WV HB5556

Authorizes the West Virginia Department of Human Services to establish a pilot program setting maximum Medicaid reimbursement rates for high-cost prescription drugs based on prices in comparable industrialized nations or federal most-favored-nation pricing

Limits the pilot to select drugs with significant Medicaid cost impact, excluding medications without appropriate international price comparisons

Grants the department authority to negotiate supplemental rebates with manufacturers and establish exceptions to prevent drug shortages or access disruptions

Caps the pilot program at three years unless extended by the Legislature, with annual reports due by December 1 to the Joint Committee on Government and Finance

Applies only to the state Medicaid program and does not require participation by private insurers or alter existing pharmaceutical benefit contracts